 |
|
| Blog results | Results 1 - 10 of about 4,362 for permanent atrial fibrillation. (0.26 seconds) |
| Sorted by relevance Sort by date |
| Related Blogs: | Atrial Fibrillation Blog - http://www.atrialfibrillationblog.com/ ATTRACTcme - http://attractcme.blogspot.com/ | |
| 2 Dec 2009 Multaq® is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Multaq® discovered and developed by sanofi-aventis ... PharmaNews.eu - http://www.pharmanews.eu/component/content/frontpage - References [ More results from PharmaNews.eu ] |
| 30 Nov 2009 The EU has approved Sanofi-Aventis's Multaq (dronedarone) for adult clinically stable patients with a history of, or current non-permanent, atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Scrip News - Home - RSS - http://www.scripnews.com/home/ |
| 27 Nov 2009 by FX These patients tend to be older, and atrial fibrillation is more likely to be chronic. Paroxysmal atrial fibrillation may progress to permanent atrial fibrillation, and aggressive attempts to restore and maintain sinus rhythm may ... H Panji Irawan - http://panji1102.blogspot.com/ [ More results from H Panji Irawan ] |
| 30 Nov 2009 According to PharmaTimes, the European Commission has granted marketing authorisation for dronedarone (Multaq®), indicated for adult clinically stable patients with a history of, or current non-permanent atrial fibrillation to prevent ... NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/ [ More results from NeLM - News ] |
| 14 Nov 2009 by Recordaf Registry The CHMP has recommended the approval of Multaq(R) in adult clinically stable patients with history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. ... PR Hub - http://blog.taragana.com/pr/ - References [ More results from PR Hub ] |
| 20 Nov 2009 by Mellanie RECORD AF Registry Findings on Rate Control vs. Rhythm Control For Afib, Including Transition to Permanent Atrial Fibrillation. Atrial Fibrillation Blog - http://atrialfibrillationblog.com/ [ More results from Atrial Fibrillation Blog ] |
| 28 Nov 2009 The treatment has been indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation to prevent recurrence of AF or to lower ventricular rate. The approval is based on a data package ... PharmaTimes World News - http://www.pharmatimes.com/ |
| 18 Nov 2009 by Chou, C.-Y., Kuo, H.-L., Wang, S.-M., Liu,... Conclusion. Patient survival is not different in patients with paroxysmal and permanent atrial fibrillation. However, patients with paroxysmal AF are more at risk for the development of TEE than those with permanent AF. Nephrology Dialysis Transplantation - Advance... - http://ndt.oxfordjournals.org/ |
| 15 Nov 2009 by News Online After one year, 54 percent of patients on rate-control strategy had developed permanent atrial fibrillation compared with 13 percent of patients in the rhythm-control strategy group. In RecordAF, a high number of patients (18%) suffered ... PRESSEMITTEILUNGEN - http://www.blogspan.net/presse/ - References [ More results from PRESSEMITTEILUNGEN ] |
| 30 Nov 2009 Multaq is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. ... Current R&D of Pharmaceutical - http://www.cradop.com/component/content/frontpage.html |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
